Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy
The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.
The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.
Source: CNBC Top. Read the original report: https://www.cnbc.com/2026/09/14/novo-nordisk-rebrands-to-novo-ceo-mike-doustdar.html
Related stories
The extreme engineering of aircraft windows
Few companies have the technology to make aircraft windows which are getting harder to make.
We are all new job starters - here's how we got through the first few days
Four recent job starters share their tips on what helped them have a smooth transition and survive their first few days.
Complaints to watchdog about water firms jump 84%
Many complaints were about affordability, after customers saw steep hikes to bills.
Mitch McConnell returns to Senate after three-month health absence
The 84-year-old Kentucky Republican is back in Washington after a fall, hospitalization, pneumonia and weeks of rehabilitation kept him away from the Senate.